HERCULES, CA--(Marketwire - November 05, 2007) - Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the introduction to the U.S. market of its MRSASelect™ test, a chromogenic medium used for the rapid screening of MRSA (methicillin-resistant Staphylococcus aureus). Bio-Rad received FDA clearance for marketing its MRSASelect test in the U.S. in September. With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect test can identify MRSA carriers in 24 hours. The MRSASelect test was introduced in Canada in 2005 and today it is the market leader there.
